Src Continues Aging: Current and Future Clinical Directions
Published version of a preprint
The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Abstract
Aberrant activation of members of the Src family of nonreceptor protein tyrosine kinases is common in solid tumor malignancies and may contribute to the development and/or progression of these tumors. As a result, four Src inhibitors are now in more than 50 clinical trials for at least 14 different types of solid tumors. In this review, we briefly discuss the preclinical rationale for Src inhibitors, the development strategies most likely to be successful in the clinic, and the rationale for Src inhibitors in combination with other agents as part of a more comprehensive therapeutic strategy. As the use of Src family inhibitors in clinical trials on solid tumors is in its infancy, further studies on the roles of Src family kinases in tumor progression, chemoresistance, epidermal-to-mesenchymal transition, and other properties of tumor progression will be important in designing the most effective clinical trials using these inhibitors.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recently, however, Src family kinases have been implicated in drug resistance [5, 6].”
From Dasatinib, a Src inhibitor, sensitizes liver metastatic colorectal carcinoma to oxaliplatin in tumors with high levels of phospho-Src (2016) · cites this paper as [5]
Citations
Cites
Blume-Jensen, P., & Hunter, T. (2001) · Nature · doi:10.1038/35077225 · Cited by 3,738
Matrix Metalloproteinase Inhibitors and Cancer—Trials and Tribulations
Coussens, L. M., Fingleton, B., & Matrisian, L. M. (2002) · Science · doi:10.1126/science.1067100 · Cited by 2,761
CELLULAR FUNCTIONS REGULATED BY SRC FAMILY KINASES
Thomas, S. M., & Brugge, J. S. (1997) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.13.1.513 · Cited by 2,498
Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice
Soriano, P., Montgomery, C., Geske, R., & Bradley, A. (1991) · Cell · doi:10.1016/0092-8674(91)90499-o · Cited by 2,016
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias
Talpaz, M., Shah, N. P., Kantarjian, H., Donato, N., Nicoll, J., Paquette, R., Cortes, J., O'Brien, S., Nicaise, C., Bleickardt, E., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055229 · Cited by 1,760
Yeatman, T. J. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1366 · Cited by 1,113
A SARCOMA OF THE FOWL TRANSMISSIBLE BY AN AGENT SEPARABLE FROM THE TUMOR CELLS
Rous, P. (1911) · Journal of Experimental Medicine · doi:10.1084/jem.13.4.397 · Cited by 1,051
Src family kinases in tumor progression and metastasis
Summy, J. M., & Gallick, G. E. (2003) · Cancer and Metastasis Reviews · doi:10.1023/a:1023772912750 · Cited by 827
Self-citationShirota, Y., Stoehlmacher, J., Brabender, J., Xiong, Y.-P., Uetake, H., Danenberg, K. D., Groshen, S., Tsao-Wei, D. D., Danenberg, P. V., & Lenz, H.-J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.23.4298 · Cited by 610
Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation
Mukhopadhyay, D., Tsiokas, L., Zhou, X.-M., Foster, D., Brugge, J. S., & Sukhatme, V. P. (1995) · Nature · doi:10.1038/375577a0 · Cited by 595
Research works printed but not linked: 6
- Desgrosellier J, Prevost N, Barnes L, Shattil S, Cheresh D. Disruption of an integrin αvβ3/c-src complex inhibits αvβ3-mediated tumor progression and metastasis. In: Proceedings of the 97th Annual Meeting of the American Association for Cancer Research, April 14-18, 2007, Los Angeles, California. p. 2186.
- Verbeek BS, Vroom TM, Adriaansen-Slot SS, et al. c-Src protein expression is increased in human breast cancer. An immunohistochemical and biochemical analysis. J Pathol 1996;180:383–8. · DOI · Paper page
- Park SI, Gallick GE. c-Src activation in the tumor-associated endothelial cells contributes to the lymph node metastases of prostate cancer cells. In: Proceedings of the 97th Annual Meeting of the American Association for Cancer Research, April 14-18, 2007, Los Angeles, California. p. 3002.
- Zhang J, Kalyankrishna S, Wislez M, et al. Src-Family Kinases are activated in non-small cell lung cancer and promote the survival of EGFR-dependent cell lines. In: Proceedings of the 97th Annual Meeting of the American Association for Cancer Research, April 14-18, 2007, Los Angeles, California. p. 2064.
- Kopetz S, Wu J, Davies M, et al. Synergistic activity of Src and EGFR inhibitors in colon cancer. In: Proceedings of the 97th Annual Meeting of the American Association for Cancer Research, April 14-18, 2007, Los Angeles, California p. 4079.
- Nakagawa T, Tanaka S, Suzuki H, et al. Overexpression of the csk gene suppresses tumor metastasis in vivo. Int J Cancer 2000;88:384–91. · doi:10.1002/1097-0215(20001101)88:3<384::aid-ijc10>3.0.co;2-b · Paper page
Cited by
The Interleukin-8 Pathway in Cancer
Waugh, D. J. J., & Wilson, C. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4843 · Cited by 2,103
Src kinases as therapeutic targets for cancer
Kim, L. C., Song, L., & Haura, E. B. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.129 · Cited by 700
“The combination of PP1 and gefitinib has shown enhanced effects on EGFR-dependent tumors, and this strategy has been successfully used in clinical trials with dasatinib and erlotinib”
MethodThe CXCL8-CXCR1/2 pathways in cancer
Liu, Q., Li, A., Tian, Y., Wu, J. D., Liu, Y., Li, T., Chen, Y., Han, X., & Wu, K. (2016) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2016.08.002 · Cited by 662
“CXCL8 signalling is positively correlated with an increase in phosphorylation of Src-kinases and FAK in cancer cells, which contributes to cell proliferation, cell survival, and chemoresistance [29,30].”
BackgroundSrc signaling in cancer invasion
Guarino, M. (2010) · Journal of Cellular Physiology · doi:10.1002/jcp.22011 · Cited by 426
“Indeed, small-molecule inhibitors of Src, including ATP-binding site competitive inhibitors—such as dasatinib, SKI-606 (bosutinib) and AZD0530—and substrate-binding site inhibitors—such as KXO1—are currently undergoing clinical trials (Summy and Gallick, 2006; Kopetz et al., 2007).”
BackgroundVaults and the major vault protein: Novel roles in signal pathway regulation and immunity
Berger, W., Steiner, E., Grusch, M., Elbling, L., & Micksche, M. (2009) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-8364-z · Cited by 253
Metadata
- Authors
- Kopetz, S., Shah, A. N., & Gallick, G. E.
- Affiliations
- 1Gastrointestinal Medical Oncology, Departments of
- The University of Texas MD Anderson Cancer Center (US)
- 2Cancer Biology, and
- Venue
- Clinical Cancer Research
- Published
- 2007-12-15
- Volume
- 13
- Issue
- 24
- Pages
- 7232-7236
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2171629680
- Cited by
- 111
- References
- 54
- Citations by year
- 2025: 1 · 2024: 1 · 2023: 4 · 2022: 2 · 2021: 3 · 2020: 3 · 2019: 3 · 2018: 5 · 2017: 3 · 2016: 8 · 2015: 4 · 2014: 6 · 2013: 10 · 2012: 12
- FWCI
- 1.43
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5p20ca101936-05)
- National Cancer Institute (5 P20 CA101936, U54CA090810, T-32 CA 09599, T32CA009599, K12CA088084)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Keywords
- Src family kinases, Src kinase inhibitor, non-receptor tyrosine kinase, solid tumors, tumor progression, chemoresistance, combination therapy, clinical trials, kinase inhibitors
- MeSH terms
- Animals, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Clinical Trials as Topic, Enzyme Inhibitors, Humans, Neoplasms, src-Family Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Src Continues Aging: Current and Future Clinical Directions. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-07-1902
- The paper
- Kopetz, S., Shah, A. N., & Gallick, G. E. (2007). Src Continues Aging: Current and Future Clinical Directions. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-07-1902
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.